Large prospective trials with robust inclusion criteria and pathologic confirmation of lesions would be of value to validate the diagnostic efficiency of PSMA PET/CT in RCC, particularly in patients at high risk for metastatic disease at initial staging, response assessment, or surveillance monitoring; in patients with oligometastatic disease; and in patients who can potentially be considered for future radioligand PSMA-targeted therapy. The gene discussed is FOLH1; the disease is renal cell carcinoma.